BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol 2021; 27(21): 2727-2757 [PMID: 34135551 DOI: 10.3748/wjg.v27.i21.2727] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Martinez MG, Combe E, Inchauspe A, Mangeot PE, Delberghe E, Chapus F, Neveu G, Alam A, Carter K, Testoni B, Zoulim F. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. mBio 2022;:e0288821. [PMID: 35389262 DOI: 10.1128/mbio.02888-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Khan IW, Dad Ullah MU, Choudhry M, Ali MJ, Ali MA, Lam SLK, Shah PA, Kaur SP, Lau DTY. Novel Therapies of Hepatitis B and D. Microorganisms 2021;9:2607. [PMID: 34946209 DOI: 10.3390/microorganisms9122607] [Reference Citation Analysis]
3 Hozáková L, Vokatá B, Ruml T, Ulbrich P. Targeting the Virus Capsid as a Tool to Fight RNA Viruses. Viruses 2022;14:174. [DOI: 10.3390/v14020174] [Reference Citation Analysis]
4 Vermes T, Kielpinski M, Henkel T, Pericàs MA, Alza E, Corcuera A, Buschmann H, Goldner T, Urban A. An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators. Anal Methods 2021. [PMID: 34918017 DOI: 10.1039/d1ay01227d] [Reference Citation Analysis]
5 Knolle PA, Huang LR, Kosinska A, Wohlleber D, Protzer U. Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. Vaccines (Basel) 2021;9:1333. [PMID: 34835264 DOI: 10.3390/vaccines9111333] [Reference Citation Analysis]
6 Li X, Liu Y, Yao H, Wang M, Gao L, Lou J, Mao J, Wu W, Zhou Y, Tang Y, Yan W, Hu Y, Ding C, Chen S, Niu J, Ding Y. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial. Antimicrob Agents Chemother 2022;:e0009422. [PMID: 35404074 DOI: 10.1128/aac.00094-22] [Reference Citation Analysis]
7 Li S, Li N, Yang S, Deng H, Li Y, Wang Y, Yang J, Lv J, Dong L, Yu G, Hou X, Wang G. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. International Immunopharmacology 2022;109:108842. [DOI: 10.1016/j.intimp.2022.108842] [Reference Citation Analysis]
8 Zhang Y, Guo M, Zhang X, Zhang N, Zhu P, Wang H. Multiple optimizations of recombinant plasmid for improving expression of Hepatitis B core antigen in Escherichia coli. Protein Expr Purif 2022;:106127. [PMID: 35660658 DOI: 10.1016/j.pep.2022.106127] [Reference Citation Analysis]